Kuros biosciences usa, inc. announces an exclusive strategic agreement with the medtronic spinal division

Medtronic will act as the exclusive sales agent of magnetostm for kuros biosciences usa, inc. in mutually agreed upon sales territories for use in spine surgeries kuros will work collaboratively to sell, market and provide support services to medtronic's sales force kuros will keep responsibility for contracts, hospital partnerships and the recognition of revenue from sales kuros will continue to sell directly in non-contracted territories as well as in markets outside of spine this agreement transforms an initial trial agreement into a strategic alliance schlieren, switzerland / accesswire / january 7, 2025 / kuros biosciences usa inc., ("kuros"), a wholly owned subsidiary of kuros biosciences ag, a global leader in advanced musculoskeletal bone healing technologies, today announced a strategic five-year, exclusive sales agency agreement with medtronic, a leading global healthcare technology company. the agreement provides medtronic with exclusivity in certain spine geographies within the u.s. market, underscoring a shared commitment to expanding access to kuros' pioneering magnetos bone grafting technology.
MDT Ratings Summary
MDT Quant Ranking